1. In Vivo
  2. >>Leadership

Robotics Player CMR Has Critical MAS In Its Sights

‘Think Laparoscopically, Act Robotically’ Must Be The Dictum Says Business Development Chief

 
• By Ashley Yeo

Robotic-assisted surgery is moving into a different phase of growth. New competitors with new ideas are coming into the industry and user awareness has been enhanced. UK scale-up CMR Surgical views these as healthy developments, says business development chief Bertrand Weil.

Alamy
(Alamy Stock Photo)

Bertrand Weil has had a whirlwind six months since joining robotic surgery technology company CMR Surgical as chief business development officer in fall 2021.

His appointment at the Cambridge, UK company came a few weeks after it had secured its $600m series D investment to develop the Versius minimal access surgery (MAS) tool. The proceeds of that will be used variously to consolidate the company’s position and expand into new markets beyond the 20 in which it is already commercially active

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

More from In Vivo

Protagonist’s Patel: Building A Differentiated Peptide Platform With Strategic Patience

 
• By David Wild

After revolutionizing the peptide therapeutic landscape, CEO Dinesh Patel reflects on the journey from surviving the 2008 financial crisis to developing a platform now poised to deliver back-to-back blockbuster approvals.

With 75 Pipeline Candidates, TIL Therapies Gain Momentum in Solid Tumor Space

 
• By David Wild

Tumor infiltrating lymphocyte therapies show promise for solid tumors, with a first FDA approval, but face manufacturing and access challenges as development continues.

NewAmsterdam’s Davidson On Reviving “Failed” Drug Class To Fill Cardiovascular Treatment Gap

 
• By David Wild

After a string of high-profile failures by big pharma, Michael Davidson is positioning his company's CETP inhibitor as the next breakthrough in cardiovascular medicine. The body of data to support this position is growing.